Skip to main content

Table 2 Comparison between groups regards pulmonary function, SGRQ score, and 6MWT at pretreatment and 6 months post-treatment

From: Evaluation of the efficacy of pirfenidone in progressive chronic hypersensitivity pneumonitis

  Group 1 Group 2 t P
FVC (ml) 1287.6 ± 106.79 1276.0 ± 106.74 0.344 0.733
FVC% predicted 55.75 ± 4.26 57.45 ± 6.16 0.200 0.842
6MWT (m) 287.5 ± 33.06 290.0 ± 28.383 − 0.255 0.800
PaO2 at rest(mmHg) 64.75 ± 2.31 62.85 ± 4.24 − 1.892 0.121
SaO2 93.5 ± 2.48 92.5 ± 2.63 − 1.792 0.142
Estimated PAP 35.0 ± 5.36 33.25 ± 7.74 1.795 0.081
SGRQ SCORE 37.2 ± 1.43 37.85 ± 2.42 − 0.995 0.326
FVC (ml) 6 M 1265.55 ± 215.15 1100.5 ± 109.46 4.031 0.00**
FVC% predicted 6 M 48.85 ± 6.42 44.5 ± 4.53 3.231 0.002*
6MWT 6 M 310.0 ± 74.09 267.0 ± 37.98 2.356 0.028*
PAP 6 M 33.0 ± 6.56 36.8 ± 5.95 − 2.186 0.037*
SaO2 6 M 94.15 ± 3.52 87.0 ± 3.07 2.745 0.017*
PaO2 6 M 66.05 ± 2.81 54.9 ± 3.53 10.113 0.00**
SGRQ SCORE 6M 38.25 ± 2.35 44.5 ± 4.52 6.789 0.00**
  1. *Significant difference
  2. **refer to highly significant results
  3. FVC forced vital capacity, 6MWT 6-min walking test, PaO2 partial pressure of oxygen in arterial blood, SaO2 oxygen saturation in arterial blood, PAP pulmonary artery pressure, SGRQ St. George’s Respiratory Questionnaire